You can write in Portuguese, English, Spanish or French. The search doesn't link to accents or uppercase letters, separates the words (all must appear) and also searches for the equivalent word in other languages: "transplant" finds "transplant" and "trasplante". Searches in the original titles, translated titles into Portuguese, descriptions and abstracts. MielomaAI.
In the last 3 months. From the older news, only the title and link remain in the archive. Those that have about 1 year may no longer be up to date
Looking for words: daratumumab. Saltar para: Recent news (13) · My Hematology (5) · explanations (3) · file (24)
Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System AnalysisOncodaily · 11:23 TratamentosTeclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneASCO Publications (Reino Unido) · 21:20 Doentes e associaçõesReino Unido
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
CHMP backs TALVEY plus daratumumab for earlier myeloma usePharmaTimes (Reino Unido) · 07:00 Acesso e saúde públicaReino UnidoRecommendation supports second-line combination option
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myelomaGlobeNewswire (Internacional) · 07:00 Acesso e saúde públicaInternacionalIf approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple...
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...Business Wire (Internacional) · 07:00 TratamentosInternacional
Overview | Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable | GuidanceNICE website (Reino Unido) · 07:00 TratamentosReino Unido- European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of careGlobeNewswire (Internacional) · 07:00 TratamentosInternacional
Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of...
Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026Oncodaily · 18:05 InvestigaçãoBen Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,
The Tocantins State Government is expanding oncological treatment by incorporating a high-cost medication.Agência Tocantins (Brazil) · 14:27 Access and public healthBrazilPTThe first administration of daratumumab was performed on a patient with multiple myeloma attended at the HGP.
EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple MyelomaCancerNetwork (EUA) · 13:13 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myelomaMyeloma Patients Europe (Europa) · 10:49 Acesso e saúde públicaEuropaOn 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together with pomalidomide, for myeloma patients who have received at least one previous line of treatment. The CHMP is…
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple MyelomaTargeted Onc (EUA) · 07:00 Acesso e saúde públicaEUAThe iberdomide-daratumumab-dexamethasone regimen was approved based on superior MRD negativity rate vs standard of care in relapsed/refractory multiple myeloma.
Click on an article to open it on the side with the summary. MielomaAI And the link to the source.
The inclusion of daratumumab in first-line treatment allows a greater number of patients to access this drug in combination with protocols such as Rd or VMP and VTd.InterviewsMy Hematologia · May 12, 2022This article discusses how daratumumab, a new drug, is being used in the treatment of multiple myeloma, a serious illness. The results of several studies have shown that this medication, when used with other treatments, can help improve patients’ health. Read more →
Professor Doctor Catarina Geraldes highlights positive results from the addition of daratumumab to VMP and Rd schemes in the treatment of MM.InterviewsMy Hematologia · November 12, 2021This article reports on a presentation by Dr. Catarina Geraldes at the meeting of the Portuguese Society of Hematology, where data on the use of the antibody daratumumab in the treatment of multiple myeloma were shared. Read more →
Incorporating this drug into a early phase of MM will have significant advantages in terms of responses and survival for these patients.InterviewsMy Hematologia · May 12, 2022Daratumumab is a new medication that is being used in the treatment of multiple myeloma (MM) as part of an initial treatment plan. This medication, in combination with other existing treatments, has shown very positive results in clinical trials. Read more →
This approval significantly changes the landscape and first-line treatment options for multiple myeloma.InterviewsMy Hematologia · May 12, 2022The daratumumab, a medication that targets specific myeloma cells, has been approved for use at the very beginning of treatment. Expert Professor Paulo Lúcio believes that this may improve how multiple myeloma is treated, particularly in the early stages of the disease. Read more →
Best of 2020: Stay up to date with the latest clinical advances in Haematology-OncologyEventsMy Hematologia · February 1, 2021This event, called Best of 2020, was created to help healthcare professionals understand the latest advances in the treatment of various types of blood cancer, such as multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia. Read more →
- Anti-CD38
- Antibodies (daratumumab, isatuximab) that bind to the CD38 protein, which is very prevalent in myeloma cells, and mark them for destruction by the immune system.
- Smouldering myeloma
- Protein M of 3 g/dL or more, or 10% to 60% plasma cells in the bone marrow, but without CRAB signs. How to manage or treat: Close monitoring (every 3 or 6 months) with imaging tests. In high-risk latency, daratumumab may be administered or entry into a clinical trial may be considered. Risk: Approximately 10% per year during the first 5 years. High risk when 2 or 3 of the following are present: more than 20% plasma cells, protein M above 2 g/dL, light chain ratio above 20. See the film "Types of myeloma" →
- AL Amyloidosis
- The SHG fold and deposit in the heart, kidneys, nerves, or liver. How to manage it: Treatment against plasmacytoid cell clones (e.g., daratumumab with bortezomib, cyclophosphamide and dexamethasone) and care for affected organs. Risk: Primarily depends on the heart. See the film "Types of myeloma" →
Access and public health
- The U.S. FDA grants accelerated approval to the first CELMoD therapy from Bristol Myers Squibb, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Business Wire · 13/08/2026
- The U.S. FDA grants accelerated approval to the CELMoD therapy from Bristol Myers Squibb, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Bristol Myers Squibb · August 13, 2026
- FDA approves iberdomide with daratumumab and dexamethasone for relapsed/refractory myeloma ↗ · OncLive · 13/08/2026
- Johnson & Johnson receives approval from Anvisa for TECVAYLI® (teclistamabe) in combination with DALINVI® (daratumumab) subcutaneous (SC) for relapsed or refractory multiple myeloma, expanding treatment options available for patients ↗ · PR Newswire · 18/06/2026
- FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma · OncLive · 05/03/2026
- FDA approves quadruplet with daratumumab in multiple myeloma without indication for transplant ↗ · Oncology News Central · 28/01/2026
- FDA approves daratumumab and hialuronidase in combination with VRd in multiple myeloma ↗ · The ASCO Post · January 27, 2026
- Johnson & Johnson is seeking approval from the EMA for the combination teclistamab–daratumumab. · PharmaTimes · 06/01/2026
- Darzalex (daratumumab) authorised for use in an inpatient setting ↗ 4 years ago · www.netfarma.pt · 19/04/2022
- FDA approves new use of daratumumab in multiple myeloma ↗ 9 years · National Cancer Institute (.gov) · 09/12/2016
- DARZALEX® (daratumumab) approved by the FDA: the first human monoclonal antibody anti-CD38 available to treat multiple myeloma ↗ 11 years · Johnson & Johnson · November 16, 2015
Patients and associations
- Belantamab mafodotina, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma: updated overall survival and efficacy from the phase 3 DREAMM-7 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 3 Trial IFM2017-03: scheme with less dexamethasone, with daratumumab and lenalidomida, for frail patients with newly diagnosed multiple myeloma ↗ about 1 year · International Myeloma Society · January 30, 2025
Treatments
- The new TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hialuronidase-fihj) demonstrate the power of a bispecific combination in relapsed or refractory multiple myeloma at the start of treatment. ↗ · PR Newswire · 06/13/2026
- Teclistamab with daratumumab in relapsed or refractory multiple myeloma ↗ · The New England Journal of Medicine · 10/12/2025
- Project information | Daratumumab for treating high-risk smouldering multiple myeloma [D10] | Guidance ↗ 2 years · NICE website · 10/04/2024
- Daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma ↗ 2 years · The New England Journal of Medicine · 12/12/2023
- Summary | Daratumumab with lenalidomide and dexamethasone in the treatment of multiple myeloma who are not treated when transplantation is not possible | Recommendation ↗ 3 years · NICE website · 25/10/2023
- Teclistamab with daratumumab in multiple myeloma in relapse or refractory after one or more treatments (ID6201) ↗ 4 years ago · NICE website · 24/10/2022
- Summary | Daratumumab alone in multiple myeloma in relapse and refractory | Recommendation ↗ 4 years ago · NICE website · 13/04/2022
- Daratumumab in combination for multiple myeloma who is not treated when transplant is feasible ↗ 4 years ago · NICE website · 02/02/2022
- Daratumumab subcutaneous: another advancement in the treatment of multiple myeloma ↗ 5 years · Afya | Home · November 30, 2020
- Genmab announces submission of European approval request for daratumumab in refractory multiple myeloma ↗ 8 years · Genmab · 20/08/2018
- Official website for patients | DARZALEX® and DARZALEX FASPRO® (daratumumab) ↗ 11 years · edge.prnewswire.com · 17/11/2015
